Drug Profile
Research programme: T cell therapy - Ganymed
Alternative Names: T cell therapy research programme - GanymedLatest Information Update: 23 Dec 2016
Price :
$50
*
At a glance
- Originator Imperial Innovations
- Developer Ganymed Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 21 Dec 2016 Ganymed Pharmaceuticals has been acquired by Astellas Pharma
- 13 Mar 2014 Discontinued - Preclinical for Cancer in Germany (unspecified route)
- 17 Feb 2014 No development reported - Preclinical for Cancer in Germany (unspecified route)